MD3319963T2 - 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B - Google Patents

4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B

Info

Publication number
MD3319963T2
MD3319963T2 MDE20180505T MDE20180505T MD3319963T2 MD 3319963 T2 MD3319963 T2 MD 3319963T2 MD E20180505 T MDE20180505 T MD E20180505T MD E20180505 T MDE20180505 T MD E20180505T MD 3319963 T2 MD3319963 T2 MD 3319963T2
Authority
MD
Moldova
Prior art keywords
azaindoles
substituted
receptor modulators
glun2b receptor
glun2b
Prior art date
Application number
MDE20180505T
Other languages
English (en)
Inventor
Christa C Chrovian
Michael A Letavic
Jason C Rech
Akinola Soyode-Johnson
Jessica L Wall
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MD3319963T2 publication Critical patent/MD3319963T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

4-azaindoli substituiţi ca liganzi receptori NR2B. Astfel de compuşi pot fi utilizaƫi în modularea receptorului NR2B şi în compoziƫii şi metode pentru tratamentul stărilor de boală, tulburărilor, şi afecƫiunilor mediate de activitatea receptorului NR2B.
MDE20180505T 2015-07-09 2016-07-07 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B MD3319963T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190416P 2015-07-09 2015-07-09
PCT/US2016/041339 WO2017007938A1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
MD3319963T2 true MD3319963T2 (ro) 2020-05-31

Family

ID=56497884

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180505T MD3319963T2 (ro) 2015-07-09 2016-07-07 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B

Country Status (25)

Country Link
US (2) US9963447B2 (ro)
EP (1) EP3319963B1 (ro)
JP (2) JP6964576B2 (ro)
KR (1) KR20180026760A (ro)
CN (1) CN108026094B (ro)
AU (1) AU2016291158B2 (ro)
BR (1) BR112018000468A2 (ro)
CA (1) CA2991765C (ro)
CY (1) CY1123007T1 (ro)
DK (1) DK3319963T3 (ro)
EA (1) EA033197B1 (ro)
ES (1) ES2781867T3 (ro)
HK (1) HK1255160A1 (ro)
HR (1) HRP20200410T1 (ro)
HU (1) HUE047460T2 (ro)
IL (1) IL256758A (ro)
LT (1) LT3319963T (ro)
MA (1) MA42397B1 (ro)
MD (1) MD3319963T2 (ro)
MX (1) MX2018000352A (ro)
PL (1) PL3319963T3 (ro)
PT (1) PT3319963T (ro)
SI (1) SI3319963T1 (ro)
WO (1) WO2017007938A1 (ro)
ZA (1) ZA201800827B (ro)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
ES2791252T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Pirazoles
CA2991765C (en) * 2015-07-09 2023-10-03 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as glun2b receptor modulators
AU2017217542B2 (en) 2016-02-10 2021-06-03 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
EP3774732A4 (en) * 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
JP2022538795A (ja) 2019-06-14 2022-09-06 ヤンセン ファーマシューティカ エヌ．ベー． ピラジンカルバメート及びＧｌｕＮ２Ｂ受容体調節因子としての使用
CA3143102A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
CA3143276A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
MX2021015506A (es) 2019-06-14 2022-02-10 Janssen Pharmaceutica Nv Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b.
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
CN114621125A (zh) * 2020-12-14 2022-06-14 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100368411C (zh) * 2002-03-28 2008-02-13 卫材R&D管理有限公司 作为c-Jun N-末端激酶抑制剂用于治疗神经变性疾病的7-氮杂吲哚类化合物
AR047744A1 (es) 2004-02-18 2006-02-15 Nps Pharma Inc Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US7807704B2 (en) * 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008145616A1 (en) 2007-05-25 2008-12-04 Abbott Gmbh & Co. Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009005821A1 (en) 2007-07-03 2009-01-08 Edward Scott Carlson Support apparatus for climbing plants
EP2194045A4 (en) 2007-08-30 2011-09-21 Takeda Pharmaceutical SUBSTITUTED PYRAZOLE DERIVATIVE
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
JP2011516417A (ja) 2008-03-27 2011-05-26 エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
AU2009304293B2 (en) * 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
ES2554375T3 (es) 2008-11-25 2015-12-18 University Of Rochester Inhibidores de las MLK y métodos de uso
TWI491606B (zh) * 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
US9650358B2 (en) * 2013-03-13 2017-05-16 Abbvie Inc. Pyridine CDK9 kinase inhibitors
CA2903293C (en) * 2013-03-15 2020-10-13 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
ES2791252T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Pirazoles
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
CA2991765C (en) 2015-07-09 2023-10-03 Janssen Pharmaceutica Nv Substituted 4-azaindoles and their use as glun2b receptor modulators
AU2017217542B2 (en) 2016-02-10 2021-06-03 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途

Also Published As

Publication number Publication date
US20170008890A1 (en) 2017-01-12
EA033197B1 (ru) 2019-09-30
CA2991765A1 (en) 2017-01-12
MA42397B1 (fr) 2020-02-28
AU2016291158A1 (en) 2018-02-01
EA201890245A1 (ru) 2018-06-29
DK3319963T3 (da) 2020-02-03
HRP20200410T1 (hr) 2020-08-21
CN108026094A (zh) 2018-05-11
MX2018000352A (es) 2018-08-15
PL3319963T3 (pl) 2020-06-01
JP2018520170A (ja) 2018-07-26
IL256758A (en) 2018-03-29
US10377753B2 (en) 2019-08-13
US9963447B2 (en) 2018-05-08
AU2016291158B2 (en) 2020-04-30
CY1123007T1 (el) 2021-10-29
PT3319963T (pt) 2020-04-09
EP3319963B1 (en) 2020-01-08
ZA201800827B (en) 2019-09-25
BR112018000468A2 (pt) 2018-09-18
SI3319963T1 (sl) 2020-02-28
JP6964576B2 (ja) 2021-11-10
EP3319963A1 (en) 2018-05-16
US20180208595A1 (en) 2018-07-26
KR20180026760A (ko) 2018-03-13
CA2991765C (en) 2023-10-03
JP7369743B2 (ja) 2023-10-26
ES2781867T3 (es) 2020-09-08
HK1255160A1 (zh) 2019-08-09
JP2021193099A (ja) 2021-12-23
WO2017007938A1 (en) 2017-01-12
CN108026094B (zh) 2021-02-09
HUE047460T2 (hu) 2020-04-28
LT3319963T (lt) 2020-03-25

Similar Documents

Publication Publication Date Title
MD3319963T2 (ro) 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B
EA201790434A1 (ru) Модуляторы каналов
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
MX2021015632A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
NZ737399A (en) Ccr2 modulators
MX2021009309A (es) Modulacion de la actividad del complemento.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2015012334A (es) Metodos y composiciones para el control de malezas.
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MX2017001290A (es) Composicion para el tratamiento de telas que comprende una nanoemulsion de polimero de aminosiloxano.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
WO2015120138A3 (en) AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
EP4219507A3 (en) Thienopyrimidinone nmda receptor modulators and uses thereof
PH12016501393B1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
EA201691493A1 (ru) Замещенные n-арилпиридиноны
TW201613884A (en) Selective NR2B antagonists
EA201792456A1 (ru) Ферментёр для получения псевдопластической среды